Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Why adult ADHD diagnoses rose: recognition, overdiagnosis or access?

    About half of the 15.5 million US adults with an ADHD diagnosis in 2023 were diagnosed as adults, and new stimulant prescriptions rose fastest among adults aged 20 to 39 and women during the pandemic.[1][2] Researchers disagree on how much reflects overdue recognition, overdiagnosis or easier telehealth access, and FDA-authored researchers said more work is needed to tell unmet need from overprescribing.[3][4][2]

    Editor reviewedStrict sourcingUpdated AnalysisMental health, Health and medicine, Tech policy
    Show:

    Adult ADHD diagnoses and stimulant prescriptions have grown quickly, and the reasons are disputed.[5][2] This analysis separates sourced facts from interpretation and sets out three competing explanations. Facts are labelled by evidence type: randomised trials, observational studies and surveys.

    This page is not medical advice and does not diagnose anyone; talk to a clinician about your own care. If you are struggling or having thoughts of suicide, help is available: call or text 988 in the US, call Samaritans on 116 123 in the UK and Ireland, or find a line at findahelpline.com.

    What the data show

    • Survey data: in 2023, 15.5 million US adults (6.0%) reported a current ADHD diagnosis, and about half were diagnosed in adulthood.[6][1] Among children, about 1 million more had ever been diagnosed in 2022 than in 2016.[7]
    • Prescription data: among commercially insured Americans, stimulant fills rose from 3.6% in 2016 to 4.1% in 2021. Increases topped 10% in 2020-2021 for women aged 15 to 44 and men aged 25 to 44.[8][5] An FDA-authored study found new Schedule II stimulant prescriptions rose 30% among patients aged 20 to 39 and 25% among women between the pre-pandemic and pandemic periods.[2]
    • Global prevalence: a 2021 meta-analysis estimated persistent adult ADHD at 2.58% and symptomatic adult ADHD at 6.76% worldwide.[9]
    • Telehealth: 46.0% of US adults with ADHD had used telehealth for it, and 30.5% had used telehealth to get a prescription since March 2020.[10] CDC noted that pandemic rules eased the in-person requirement for stimulant prescriptions, but its data could not show which prescriptions came from telehealth.[11]

    The overdiagnosis evidence

    A 2021 systematic scoping review of 334 studies found evidence of ADHD overdiagnosis and overtreatment in children and adolescents. Only five studies examined benefits and harms among the additional, milder cases.[4] A 2022 review argued that broader diagnostic criteria explain part of the rise, but that greater awareness, especially for women and minority groups, also matters and detection gaps persist.[3] The NHS says ADHD is thought to be recognised less often in women because inattentive symptoms are harder to spot.[12] The FDA-authored prescription study concluded that more research is needed to tell increases due to unmet need from overprescribing.[2]

    The MAHA report and the scientific record

    The May 2025 MAHA Commission assessment, from a federal commission, said research shows ADHD has the strongest evidence of overdiagnosis among youth conditions.[13] It said stimulants cause long-term height loss averaging an inch and that the only long-term trial found benefits at 14 months that were not found at 3 years.[14] It also said psychiatric drugs, including stimulants, often cause disabling and prolonged withdrawal when stopped.[15] Two studies the report cited on advertising and ADHD prescriptions could not be found; the White House called the errors formatting issues and removed the references.[16][17] The September 2025 strategy committed HHS to a working group on children’s prescribing, including stimulants.[18]

    How those statements compare with the published evidence:

    • Height: the long-term MTA follow-up (observational after the first 14 months) found children with consistent or inconsistent stimulant use were on average 2.55 cm shorter as adults than those with negligible use. That is close to the report’s figure of an inch.[19]
    • Long-term benefit: the same follow-up found extended medication use was not associated with lower symptom severity in early adulthood.[19] Network meta-analyses of randomised trials show short-term symptom benefit but too little data beyond 12 weeks.[20][21] A 2025 Swedish register study of 148,581 people linked starting medicine to lower rates of substance misuse, transport accidents and criminality over two years. This was observational evidence using a target-trial design.[22]
    • Overdiagnosis: the report’s quoted finding matches the 2021 scoping review’s conclusion about milder cases in young people. That review was limited to children and adolescents.[4]
    • Withdrawal: FDA labelling does recognise dependence. The Vyvanse label says it may produce physical dependence and lists withdrawal symptoms such as low mood, fatigue and sleep changes after abrupt stopping following prolonged use.[23] The labels’ boxed warning concerns abuse, misuse and addiction.[24] We found no tier-1 source measuring how often stimulant withdrawal is “disabling and prolonged”, the report’s wording, so that characterisation is neither confirmed nor refuted here.

    The data fit more than one story. The size of the 2020-2021 jump, concentrated in young adults and women, is consistent with both pent-up demand meeting easier access and with lowered thresholds. The surveys cannot separate these, and the prescription studies say so explicitly. The MAHA report draws on real findings about height and the limits of long-term trial evidence. But it presents them without the observational evidence of benefit, and its citation errors weakened its credibility with reporters and researchers. Evidence on overdiagnosis comes mainly from children, so applying it directly to adults diagnosed after 2020 is an extrapolation.

    Forecast (uncertain): the main near-term driver to watch is the DEA telemedicine rule, which expires on 31 December 2026 unless extended or replaced.[25] If in-person requirements return, new adult prescriptions might slow. Persistent shortages could have the same effect.[26] The HHS working group could also shape prescribing guidance, but no timetable has been published in the sources we reviewed.[18]

    See ADHD in adults for how adults are assessed, the medication guide for treatment evidence, and the shortage and telehealth tracker for dated developments.

    Competing views

    Overdue recognition

    Adult ADHD was long missed, especially in women and minority groups whose symptoms are less visible. Rising diagnoses largely reflect awareness catching up with a real condition that affects several per cent of adults worldwide.[3][12][9][1]

    Overdiagnosis risk

    Evidence of overdiagnosis is strongest in children, newly diagnosed cases skew milder, and long-term benefits of treatment for milder cases are unproven. The MAHA Commission has made this case for children.[4][13][19][27]

    Access and business models

    The 2020-2021 jump coincided with relaxed rules on prescribing stimulants by video, and some subscription telehealth firms pushed prescribing; prosecutors secured convictions in the Done Global case.[5][11][10][28][29]

    Next in the crash course

    Questions readers ask

    How many US adults have been diagnosed with ADHD?

    A CDC survey estimated 15.5 million US adults (6.0%) had a current ADHD diagnosis in 2023, and about half were diagnosed in adulthood.[6][1]

    Did stimulant prescriptions rise during the pandemic?

    Yes. The share of commercially insured people filling a stimulant prescription rose from 3.6% in 2016 to 4.1% in 2021, with increases above 10% in 2020-2021 among women aged 15 to 44 and men aged 25 to 44.[8][5]

    Is ADHD overdiagnosed?

    A 2021 scoping review found evidence of overdiagnosis and overtreatment in children and adolescents, but only five studies looked at benefits and harms for the extra, milder cases. Other reviewers stress increased recognition and continuing under-detection in women and minority groups.[4][3]

    What did the MAHA report say about ADHD?

    It said ADHD has the strongest evidence of overdiagnosis, that stimulants cause long-term height loss averaging an inch, and that long-term benefits were not found. Two studies it cited on ADHD drug advertising could not be found and were later removed.[13][14][16][17]

    What does the evidence say about the long-term effects of stimulants?

    Randomised trials show short-term symptom benefit but little long-term data. In the observational MTA follow-up, extended use was linked to about 2.5 cm less adult height and no lower symptom severity, while a 2025 Swedish register study linked starting medicine to less substance misuse, fewer transport accidents and less crime.[21][19][22]

    Sources

    · 29 claims from 22 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      About half of US adults with a current ADHD diagnosis in 2023 were diagnosed in adulthood. confirmedas of 2024-10-10

    2. [2]

      An FDA-authored study of US pharmacy data found that new Schedule II stimulant prescriptions rose 30% among patients aged 20 to 39 and 25% among female patients between the pre-pandemic and pandemic periods (April 2018 to March 2022); the authors called for research to tell unmet need from overprescribing. confirmedas of 2024-04-01

    3. [3]

      A 2022 review argued that broader diagnostic criteria explain part of the rise in ADHD diagnoses, that increased awareness among physicians and the public, especially for women and minority groups, also plays a big role, and that detection disparities remain. confirmedas of 2022-09-01

    4. [4]

      A 2021 scoping review of 334 studies found evidence of ADHD overdiagnosis and overtreatment in children and adolescents, but only five studies examined benefits and harms among additional, milder cases. confirmedas of 2021-04-01

    5. [5]

      Stimulant fills rose by more than 10% during 2020-2021 among females aged 15 to 44 and males aged 25 to 44. confirmedas of 2023-03-31

    6. [6]

      CDC estimated that 15.5 million US adults (6.0%) had a current ADHD diagnosis in 2023, based on self-report. confirmedas of 2024-10-10

    7. [7]

      About 1 million more US children had ever received an ADHD diagnosis in 2022 than in 2016. confirmedas of 2024-05-22

    8. [8]

      Among commercially insured Americans, the share with at least one stimulant prescription fill rose from 3.6% in 2016 to 4.1% in 2021, with the largest single-year increases in 2020-2021. confirmedas of 2023-03-31

    9. [9]

      A 2021 global meta-analysis estimated the prevalence of persistent adult ADHD (with childhood onset) at 2.58% and of symptomatic adult ADHD at 6.76% in 2020. confirmedas of 2021-02-11

    10. [10]

      Almost half of US adults with ADHD (46.0%) reported ever receiving telehealth services for the condition, and since March 2020 about 30.5% used telehealth to obtain an ADHD medication prescription. confirmedas of 2024-10-10

    11. [11]

      CDC's authors noted that pandemic policy changes eased the in-person requirement for stimulant prescriptions, but said their data could not show whether prescriptions came from telehealth visits. confirmedas of 2023-03-31

    12. [12]

      The NHS says ADHD is thought to be recognised less often in women than men, possibly because women more commonly have inattentive symptoms, which can be harder to recognise. confirmedas of 2025-03-19

      • ADHD in adults · NHS (nhs.uk) · 2025-03-19 · Symptoms of ADHD (retrieved 2026-10-11)
    13. [13]

      The MAHA assessment said research shows ADHD has the strongest evidence of overdiagnosis among childhood mental health conditions, quoting a finding that harms of diagnosis may outweigh benefits for youth with milder symptoms. confirmedas of 2025-05-22

    14. [14]

      The May 2025 MAHA Commission assessment stated that stimulants cause long-term height loss averaging an inch and that the only long-term trial found behaviour benefits at 14 months that were not found at 3 years. confirmedas of 2025-05-22

      • Make Our Children Healthy Again Assessment (MAHA Report) · The White House, Make America Healthy Again Commission · 2025-05-22 · Section 4, The Overmedicalization of Our Kids; continues: the only long-term trial found exclusively short-term (14-month) behavior benefits, which were not found at 3 years (retrieved 2026-10-11)
    15. [15]

      The MAHA assessment stated that antidepressants, stimulants, antipsychotics and other psychiatric drugs, when stopped, often lead to disabling and prolonged physical dependence and withdrawal symptoms. confirmedas of 2025-05-22

    16. [16]

      NOTUS reported that two studies the MAHA report cited on direct-to-consumer advertising and ADHD medication use in children could not be found in the scientific literature; CIDRAP and other outlets also reported the errors. confirmedas of 2025-05-29

    17. [17]

      The White House press secretary called the citation errors "formatting issues" and said the report would be updated, and the references to non-existent studies were later removed. confirmedas of 2025-05-30

    18. [18]

      The September 2025 MAHA strategy said HHS would form a mental health diagnosis and prescription working group to evaluate prescribing patterns for children of drugs including SSRIs, antipsychotics, mood stabilizers and stimulants. confirmedas of 2025-09-09

    19. [19]

      In the observational long-term follow-up of the MTA study, children who used stimulants consistently or inconsistently were on average 2.55 cm shorter as adults than those with negligible use, and extended medication use was not associated with lower symptom severity in early adulthood. confirmedas of 2017-03-10

    20. [20]

      A 2018 network meta-analysis of 133 double-blind randomised trials concluded that, weighing efficacy and safety, methylphenidate in children and adolescents and amphetamines in adults are preferred first-choice medicines for short-term ADHD treatment. confirmedas of 2018-08-07

    21. [21]

      The 2018 network meta-analysis did not find sufficient data to assess ADHD medicines at 26 and 52 weeks and called for funding of research on long-term effects. confirmedas of 2018-08-07

    22. [22]

      A 2025 Swedish register study emulating target trials in 148,581 people with ADHD found that starting ADHD medication was associated with lower rates of substance misuse, transport accidents and criminality over two years, but not of first accidental injuries. confirmedas of 2025-08-13

    23. [23]

      The Vyvanse label says it may produce physical dependence, and lists withdrawal symptoms after abrupt stopping or dose reduction following prolonged use of stimulants, including low mood, depression, fatigue, vivid unpleasant dreams, sleep changes and increased appetite. confirmedas of 2026-04-30

    24. [24]

      FDA labels for stimulants such as Vyvanse, Adderall XR and Concerta carry a boxed warning that they have a high potential for abuse and misuse, which can lead to substance use disorder including addiction. confirmedas of 2026-04-30

    25. [25]

      On 31 December 2025 DEA and HHS published a fourth extension of the telemedicine flexibilities, effective 1 January 2026 through 31 December 2026. confirmedas of 2025-12-31

    26. [26]

      FDA's drug shortage list has carried immediate-release amphetamine mixed salts tablets (Adderall and generics) since 12 October 2022, and the shortage was still listed as current in data updated on 9 October 2026. confirmedas of 2026-10-09

    27. [27]

      The 2025 adult network meta-analysis found ADHD medicines were not efficacious on outcomes such as quality of life, and that longer-term evidence is under-investigated. confirmedas of 2025-01-01

    28. [28]

      In November 2025 a federal jury convicted Done Global founder Ruthia He and former clinical president David Brody of conspiracy to distribute controlled substances, distribution of controlled substances and conspiracy to commit health care fraud; He was also convicted of conspiracy to obstruct justice. confirmedas of 2026-07-07

    29. [29]

      The US Attorney's Office said Cerebral gave providers financial incentives for prescribing stimulant medication to ADHD patients and did not keep adequate controls against diversion, and Cerebral admitted to the facts in a statement attached to the agreement. confirmedas of 2024-11-06

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Jan 11, 2027.

    Cite this page

    "Why adult ADHD diagnoses rose: recognition, overdiagnosis or access?." ContentLora, updated Oct 11, 2026. https://contentlora.com/analysis/adult-adhd-diagnosis-rise-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents